Health & Environmental Research Online (HERO)


Print Feedback Export to File
1519840 
Journal Article 
Effects of chronic treatment with the eNOS stimulator Impaza on penis length and sexual behaviors in rats with a high baseline of sexual activity 
Chu, X; Zhavbert, ES; Dugina, JL; Kheyfets, IA; Sergeeva, SA; Epstein, OI; Agmo, A 
2014 
Yes 
International Journal of Impotence Research
ISSN: 0955-9930
EISSN: 1476-5489 
26 
1 
35-40 
English 
23486197 
WOS:000329782100009 
has retraction 10498081 Retraction Note:
Endothelial nitric oxide synthase (eNOS) has an important role in erection, and it also affects aspects of sexual behavior. In this experiment, we determined whether a compound enhancing the activity of eNOS, Impaza, could stimulate any aspect of sexual behavior and increase penis length in rats with a high baseline of sexual activity. For comparison, the PDE5 inhibitor sildenafil was included. Male rats were orally treated with Impaza or sildenafil for 28 days. Impaza (3 ml kg(-1)) was given daily while sildenafil (3 mg kg(-1)) was given twice weekly. Tests for sexual incentive motivation and copulatory behavior were performed just before drug treatment and at days 7, 14 and 28 of treatment. In addition, the length of the protruding penis at mount, intromission and ejaculation was measured. Impaza but not sildenafil increased penis length at mount after 14 and 28 days of treatment. The compounds failed to modify sexual incentive motivation or copulatory behavior. It is suggested that Impaza enhanced intracavernous pressure, as such a pressure increase is the most likely explanation for enhanced penis length at mount. This effect, together with an absence of motivational actions, suggests that Impaza may be the most valuable treatment for erectile dysfunction.International Journal of Impotence Research advance online publication, 14 March 2013; doi:10.1038/ijir.2013.12. 
copulatory behavior; Impaza; proerectile drugs; sexual incentive motivation; sildenafil